STATE OF WISCONSIN  
CONTROLLED SUBSTANCES BOARD  
---------------------------------------------------------------------------------------------------------------------  
IN THE MATTER OF RULE-MAKING : AFFIRMATIVE ACTION  
PROCEEDINGS BEFORE THE : ORDER OF THE  
CONTROLLED SUBSTANCES BOARD : CONTROLLED SUBSTANCES BOARD  
---------------------------------------------------------------------------------------------------------------------  

FINDINGS

1. On June 1, 2022, the Department of Justice, Drug Enforcement Administration published its interim final rule in the Federal Register listing Ganaxolone into schedule V of the federal Controlled Substances Act. The scheduling action is effective June 1, 2022.

2. The Controlled Substances Board did not receive an objection to similarly listing Ganaxolone as a schedule V under ch. 961, Stats. within 30 days of the date of publication in the federal register of the interim final order listing Ganaxolone as a schedule V controlled substance.

3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing Ganaxolone as a schedule V controlled substance.

ORDER

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Ganaxolone under chapter 961, Stats. by creating the following:

CSB 2.95 Addition of Ganaxolone to schedule V. Section 961.22 (11), Stats., is created to read:

961.22 (11) Ganaxolone.

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated 07/20/22  

Douglas Englebert  
Doug Englebert, Chair  
Controlled Substances Board